All codes
L022
L022 – Newborn Screening Test for: Amino acidopathies, Fatty acid oxidation defects, Organic acidemias, Endocrinopathies, Hemoglobinopathies, Biotinidase deficiency, Galactosemia, Cystic fibrosis, Severe combined immune deficiency, Permanent hearing loss risk, Mucopolysaccharidosis type I, Spinal muscular atrophy, X-ALD (X-linked adrenoleukodystrophy)
OHIP Laboratory Medicine Code · Schedule of Benefits
Newborn Screening Test for: Amino acidopathies, Fatty acid oxidation defects, Organic acidemias, Endocrinopathies, Hemoglobinopathies, Biotinidase deficiency, Galactosemia, Cystic fibrosis, Severe combined immune deficiency, Permanent hearing loss risk, Mucopolysaccharidosis type I, Spinal muscular atrophy, X-ALD (X-linked adrenoleukodystrophy). Listed under 2.2 Biochemistry in the Schedule of Benefits for Laboratory Services (effective April 1, 2026). [Essential Specifications 15] L022 Newborn Screening Test can only be performed by the laboratory operated by the Children's Hospital of Eastern Ontario — Ottawa Children's Treatment Centre (CHEO) or a laboratory that has entered into an agreement with CHEO related to the participation of that laboratory in the provincial newborn screening program.
Ready to bill this code?
SnapBill makes OHIP billing simple — auto-filled codes, validation, and batch submission.